AbbVie Inc.

ABBVNYSEHealthcare● Active

$227.23

+$2.29(+1.02%)

Market Cap$401.5B

P/E Ratio—

52W High$244.81

52W Low$181.73

Avg Volume6.6M

Open$227.37

Beta0.31

Overview

AbbVie Inc. (ABBV) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

abbv · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for AbbVie Inc. (ABBV) measures how much investors pay for each dollar of the company's trailing earnings. ABBV's current PE ratio of 110.77x is calculated by dividing its stock price of $227.23 by its TTM earnings per share of $2.05. +104.3% elevated vs 5Y avg 54.2x

110.77x

P/E Ratio (TTM)+104.3%

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E

13.95x

FY2027 est. EPS $16.29

Based on 18 analysts

EPS (TTM)

$2.05

TTM · diluted EPS

PEG Ratio

-8.40

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · AbbVie Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2009 – 2025 · Annual

PE Ratio (TTM)

5Y Avg 54.2x

EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

Historical PE Range

Past 17 fiscal years · Front-end computed

Average

32.2x

17-yr mean

Median

20.8x

17-yr midpoint

Minimum

10.2x

Lowest year

Maximum

96.3x

Highest year

110.8x ← Now

10.2x
MinQ1 · 25%20.8x
MedianQ3 · 75%96.3x
Max

Historically Elevated

At 110.77x, ABBV's current P/E is higher than in 100% of its annual fiscal year readings over the past 17 years — historically elevated.

100th percentileHigher than 17 of 17 historical fiscal year readings

Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.

PE Ratio vs Peers

Drug Manufacturers - General · 6 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
AbbVie Inc.You ABBV	$401.5B	110.77x	+480.0%	$2.05
Amgen Inc. AMGN	$188.7B	22.84x	+19.6%	$14.33
AstraZeneca PLC AZN	$288.4B	26.53x	+38.9%	$6.62
Gilead Sciences, Inc. GILD	$160.4B	17.94x	-6.1%	$6.84
Johnson & Johnson JNJ	$560.3B	18.81x	-1.5%	$11.04
Merck & Co., Inc. MRK	$298.3B	14.43x	-24.5%	$7.30
Novo Nordisk A/S NVO	$190.9B	14.05x	-26.4%	$23.03
Industry Average 6 peers with valid PE	—	19.10x	baseline	—

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 17 years

Fiscal Year End	PE Ratio	EPS (TTM)	YoY Change
2025-12-31Latest FY2025	96.26x	$2.37	+31.0%
2024-12-31 FY2024	73.48x	$2.42	+30.4%
2023-12-31 FY2023	56.34x	$2.75	+133.0%
2022-12-31 FY2022	24.18x	$6.68	+16.5%
2021-12-31 FY2021	20.76x	$6.52	-46.3%
2020-12-31 FY2020	38.70x	$2.77	+132.6%
2019-12-31 FY2019	16.64x	$5.32	-33.4%
2018-12-31 FY2018	24.98x	$3.69	-14.1%
2017-12-31 FY2017	29.07x	$3.33	+70.4%
2016-12-31 FY2016	17.06x	$3.67	-8.8%

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

PE Ratio = Stock Price ÷ EPS (TTM)

= $227.23 ÷ $2.05 = 110.77x

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

ABBV pe ratio · 6 questions

ABBV's current PE ratio is 110.77x as of 2026-06-08, based on a stock price of $227.23 and TTM EPS of $2.05. Data sourced from Financial Modeling Prep via ABBV's SEC 10-K and 10-Q filings.

ABBV PE ratioWhat is ABBV PE ratioCurrent PE ratio of ABBVABBV PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · AbbVie Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08